Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityActive in the last 2 years

Zheng Wu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-2441-0229; OpenAlex author ID A5101997154, A5126570114. Sources: OpenAlex.

Their work

Papers
44 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
101
Papers, trials and grants by year

2013: 4 papers · 2014: 3 papers · 2015: 4 papers · 2016: 3 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 3 papers · 2021: 3 papers · 2022: 9 papers · 2023: 1 paper · 2024: 3 papers · 2025: 2 papers · 2026: 1 paper

Papers 44

  1. Nanomagnetic Hyperthermia Sensitizes Gemcitabine Chemosensitivity in Pancreatic Cancer by Inhibiting HSPB1 to Amplify ACSL4-Mediated Ferroptosis. Last author DOI 10.1002/smll.202514973↗
  2. Chlorophyllin exerts synergistic anti-tumor effect with gemcitabine in pancreatic cancer by inducing cuproptosis. Co-author DOI 10.1186/s10020-025-01180-y↗
  3. Elevated SREBP1 accelerates the initiation and growth of pancreatic cancer by targeting SOX9. Co-author DOI 10.1186/s13062-025-00595-1↗
  4. Analysis of chemoresistance characteristics and prognostic relevance of postoperative gemcitabine adjuvant chemotherapy in pancreatic cancer. Last author DOI 10.1002/cam4.7229↗
  5. Pharmacological inhibition of SREBP1 suppresses pancreatic cancer growth via inducing GPX4-mediated ferroptosis. Co-author DOI 10.1016/j.cellsig.2024.111381↗
  6. MFG-E8 induces epithelial-mesenchymal transition and anoikis resistance to promote the metastasis of pancreatic cancer cells. Co-author DOI 10.1016/j.ejphar.2024.176462↗
  7. Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2022.215976↗
  8. NNK from tobacco smoking enhances pancreatic cancer cell stemness and chemoresistance by creating a β2AR-Akt feedback loop that activates autophagy. Co-author DOI 10.1002/1878-0261.13230↗
  9. Heat shock factor 1 inhibition sensitizes pancreatic cancer to gemcitabine via the suppression of cancer stem cell-like properties. Last author DOI 10.1016/j.biopha.2022.112713↗
  10. Piezo1 act as a potential oncogene in pancreatic cancer progression. Co-author DOI 10.1016/j.lfs.2022.121035↗
  11. Thiostrepton induces ferroptosis in pancreatic cancer cells through STAT3/GPX4 signalling. Co-author DOI 10.1038/s41419-022-05082-3↗
  12. Integrated analysis of necroptosis-related lncRNAs for prognosis and immunotherapy of patients with pancreatic adenocarcinoma. Last author DOI 10.3389/fgene.2022.940794↗
  13. Huaier suppresses pancreatic cancer progression via activating cell autophagy induced ferroptosis. Co-author DOI 10.3389/fonc.2022.960858↗
  14. The effect of minimally invasive or open radical antegrade modular pancreatosplenectomy on pancreatic cancer: A multicenter randomized clinical trial protocol. Co-author DOI 10.3389/fonc.2022.965508↗
  15. Incidence and risk factors of suicide among patients with pancreatic cancer: A population-based analysis from 2000 to 2018. Co-author DOI 10.3389/fonc.2022.972908↗
  16. RASAL2 mediated the enhancement of YAP1/TIAM1 signaling promotes malignant phenotypes of pancreatic ductal adenocarcinoma. Co-author DOI 10.7150/ijbs.72204↗
  17. Arl4c promotes the growth and drug resistance of pancreatic cancer by regulating tumor-stromal interactions. Co-author DOI 10.1016/j.isci.2021.103400↗
  18. The EGFR-HSF1 axis accelerates the tumorigenesis of pancreatic cancer. Co-author DOI 10.1186/s13046-020-01823-4↗
  19. Identification of Key Genes Mutations Associated With the Radiosensitivity by Whole Exome Sequencing in Pancreatic Cancer. Co-author DOI 10.3389/fonc.2021.697308↗
  20. 2'-Hydroxyflavanone inhibits the progression of pancreatic cancer cells and sensitizes the chemosensitivity of EGFR inhibitors via repressing STAT3 signaling. Co-author DOI 10.1016/j.canlet.2019.11.041↗
  21. Cav-1 Ablation in Pancreatic Stellate Cells Promotes Pancreatic Cancer Growth through Nrf2-Induced shh Signaling. Co-author DOI 10.1155/2020/1868764↗
  22. Curcumin inhibits pancreatic cancer cell invasion and EMT by interfering with tumor‑stromal crosstalk under hypoxic conditions via the IL‑6/ERK/NF‑κB axis. Co-author DOI 10.3892/or.2020.7600↗
  23. Mouse-Derived Allografts: A Complementary Model to the KPC Mice on Researching Pancreatic Cancer In Vivo. Last author DOI 10.1016/j.csbj.2019.03.016↗
  24. Resveratrol enhances the chemotherapeutic response and reverses the stemness induced by gemcitabine in pancreatic cancer cells via targeting SREBP1. Co-author DOI 10.1111/cpr.12514↗
  25. Pancreatic Stellate Cells Facilitate Perineural Invasion of Pancreatic Cancer via HGF/c-Met Pathway. Last author DOI 10.1177/0963689719851772↗
  26. High glucose microenvironment accelerates tumor growth via SREBP1-autophagy axis in pancreatic cancer. Co-author DOI 10.1186/s13046-019-1288-7↗
  27. Curcumin inhibits superoxide dismutase-induced epithelial-to-mesenchymal transition via the PI3K/Akt/NF-κB pathway in pancreatic cancer cells. Co-author DOI 10.3892/ijo.2018.4295↗
  28. The inhibition of heme oxygenase-1 enhances the chemosensitivity and suppresses the proliferation of pancreatic cancer cells through the SHH signaling pathway. Co-author DOI 10.3892/ijo.2018.4363↗
  29. Desmoplasia suppression by metformin-mediated AMPK activation inhibits pancreatic cancer progression. Co-author DOI 10.1016/j.canlet.2016.10.019↗
  30. Circulating miRNA-21-5p as a diagnostic biomarker for pancreatic cancer: evidence from comprehensive miRNA expression profiling analysis and clinical validatio… Last author DOI 10.1038/s41598-017-01904-z↗
  31. β2-adrenogenic signaling regulates NNK-induced pancreatic cancer progression via upregulation of HIF-1α. Co-author DOI 10.18632/oncotarget.5677↗
  32. Pancreatic stellate cells contribute pancreatic cancer pain via activation of sHH signaling pathway. Co-author DOI 10.18632/oncotarget.7776↗
  33. Circulating microRNA profile predicts disease progression in patients receiving second-line treatment of lapatinib and capecitabine for metastatic pancreatic c… Co-author DOI 10.3892/ol.2016.4101↗
  34. Phase II study of lapatinib and capecitabine in second-line treatment for metastatic pancreatic cancer. Co-author DOI 10.1007/s00280-015-2855-z↗
  35. Overexpression of Nodal induces a metastatic phenotype in pancreatic cancer cells via the Smad2/3 pathway. Co-author DOI 10.18632/oncotarget.2686↗
  36. Stromal-derived factor-1α/CXCL12-CXCR4 chemotactic pathway promotes perineural invasion in pancreatic cancer. Co-author DOI 10.18632/oncotarget.3069↗
  37. miR-221/222 induces pancreatic cancer progression through the regulation of matrix metalloproteinases. Co-author DOI 10.18632/oncotarget.3686↗
  38. Upregulated miR-106a plays an oncogenic role in pancreatic cancer. Co-author DOI 10.1016/j.febslet.2014.01.007↗
  39. α-Mangostin suppresses the viability and epithelial-mesenchymal transition of pancreatic cancer cells by downregulating the PI3K/Akt pathway. Co-author DOI 10.1155/2014/546353↗
  40. Arginine deiminase augments the chemosensitivity of argininosuccinate synthetase-deficient pancreatic cancer cells to gemcitabine via inhibition of NF-κB signa… Co-author DOI 10.1186/1471-2407-14-686↗
  41. Hedgehog signaling regulates hypoxia induced epithelial to mesenchymal transition and invasion in pancreatic cancer cells via a ligand-independent manner. Co-author DOI 10.1186/1476-4598-12-66↗
  42. Pancreaticoduodenectomy combined with vascular resection and reconstruction for patients with locally advanced pancreatic cancer: a multicenter, retrospective … Co-author DOI 10.1371/journal.pone.0070340↗
  43. Biomarkers screening between preoperative and postoperative patients in pancreatic cancer. Co-author DOI 10.7314/apjcp.2013.14.7.4161↗
  44. CA 19-9 tumor marker: is it reliable? A case report in a patient with pancreatic cancer. Co-author PMID 23416865↗

Closest collaborators

The 25 strongest of 101 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Qingyong Ma · 32 shared papers, 2013–2025 · strength 3.21
  2. Weikun Qian · 17 shared papers, 2019–2025 · strength 2.19
  3. Zheng Wang · 21 shared papers, 2013–2024 · strength 2.17
  4. Cancan Zhou · 8 shared papers, 2019–2025 · strength 1.14
  5. Jiantao Mo · 5 shared papers, 2022–2026 · strength 1.02
  6. Liang Han · 8 shared papers, 2015–2025 · strength 0.95
  7. Wanxing Duan · 14 shared papers, 2013–2022 · strength 0.93
  8. Zeen Zhu · 6 shared papers, 2022–2025 · strength 0.92
  9. Xuqi Li · 14 shared papers, 2013–2025 · strength 0.92
  10. Jiguang Ma · 13 shared papers, 2013–2022 · strength 0.87
  11. Shuai Wu · 4 shared papers, 2022–2025 · strength 0.82
  12. Wunai Zhang · 5 shared papers, 2022–2025 · strength 0.80
  13. Jiaqiang Ren · 3 shared papers, 2024–2026 · strength 0.74
  14. Jianjun Lei · 12 shared papers, 2013–2021 · strength 0.74
  15. Weifan Zhang · 5 shared papers, 2022–2023 · strength 0.73
  16. Erxi Wu · 11 shared papers, 2013–2022 · strength 0.68
  17. Wei Li · 5 shared papers, 2018–2024 · strength 0.67
  18. Zhengdong Jiang · 8 shared papers, 2015–2023 · strength 0.61
  19. Simei Zhang · 4 shared papers, 2022–2023 · strength 0.58
  20. Yangyang Yue · 4 shared papers, 2020–2022 · strength 0.50
  21. Ying Xiao · 4 shared papers, 2019–2022 · strength 0.45
  22. Ruiqi Cao · 2 shared papers, 2024–2025 · strength 0.43
  23. Jie Li · 3 shared papers, 2019–2024 · strength 0.42
  24. Qinhong Xu · 9 shared papers, 2013–2017 · strength 0.39
  25. Liang Han · 5 shared papers, 2014–2022 · strength 0.36

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.